4. GRAIL Inc. (NASDAQ:GRAL)
GRAIL, Inc. (NASDAQ: GRAL) is one of the most controversial but fascinating biotech-style diagnostics stocks on this list because its story is built around one massive idea: detecting cancer earlier through a blood test. Its Galleri test is designed for multi-cancer early detection, which means the upside could be enormous if clinical evidence, regulatory progress, physician adoption, and reimbursement eventually line up. Based on latest market data, GRAIL traded at $59.65, with a market capitalization of about $2.42 billion. In the uploaded screen, GRAL showed an 18.80% 12-week price change, projected sales growth of 22.28%, and no forward P/E, which reflects the fact that this is still a loss-making scale-up story rather than a mature earnings story.
The latest quarter showed strong commercial momentum but also continued losses. In Q1 2026, GRAIL reported total revenue of $40.8 million, up 28% year over year. Galleri revenue grew 37% to $39.8 million, while test volume increased 50% to more than 56,000. The company also announced plans to integrate Galleri into the Epic electronic health record platform, which could expand access through physician workflows. However, the company still posted a net loss of $93.2 million, meaning investors need to treat this as a high-conviction, high-risk diagnostics growth stock, not a traditional value stock.
CEO Bob Ragusa said GRAIL continues to “execute commercially,” citing strong volume growth and the company’s Epic collaboration. He also highlighted upcoming detailed presentations from PATHFINDER 2 and the NHS-Galleri trial at the 2026 ASCO Annual Meeting. That matters because clinical data is the heart of the GRAL thesis. The upside is that Galleri could become a major screening tool if the evidence and coverage picture improve. The risk is equally obvious: disappointing trial interpretation, delayed FDA progress, limited insurance coverage, and cash burn could pressure the stock. Barron’s previously reported a major selloff after NHS-Galleri trial results failed to show a statistically significant reduction in late-stage cancers, which is exactly why investors need to watch the evidence closely. GRAL can be a big winner, but it is not a sleepy biotech stock.
Click next to see the following stock...
